RLMD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
13.1M
-12.8%
15.0M
-22.9%
19.5M
-4.3%
20.3M
+96.9%
10.3M
R&D
9.2M
+9.8%
8.4M
+3.8%
8.1M
+0.2%
8.1M
+100.0%
4.0M
SG&A
3.9M
-41.4%
6.6M
-41.8%
11.4M
-7.2%
12.3M
+94.9%
6.3M
Operating Income
-13096423
+12.8%
-15011027
+22.9%
-19461754
+4.3%
-20333112
-96.9%
-10327346
EBITDA
-13096423
+12.8%
-15011027
+22.9%
-19461754
+4.3%
-20333112
-96.9%
-10327346
Net Income
-13862188
-7.3%
-12914185
+32.2%
-19051956
+4.1%
-19867760
-96.9%
-10091496
EPS (Basic)
$-0.12
-9.1%
$-0.11
+50.0%
$-0.22
+33.3%
$-0.33
-10.0%
$-0.30
EPS (Diluted)
$-0.12
-9.1%
$-0.11
+50.0%
$-0.22
+33.3%
$-0.33
-10.0%
$-0.30
Shares (Diluted)
112.4M
+0.1%
112.4M
+29.8%
86.6M
+41.7%
61.1M
+84.2%
33.2M
Relmada Therapeutics (RLMD) — Financials